BACKGROUND/AIM: Adiponectin, an adipocyte-derived protein, has been shown to exert antidiabetic, anti-inflammatory, and antiatherosclerotic effects. Although recent reports show an increase in the total adiponectin levels in chronic kidney disease patients and in patients with end-stage renal disease, the nature of biodegradation and renal involvement of adiponectin is largely unknown. We aimed at determining whether the high-molecular-weight (HMW) complex of adiponectin is associated with renal insufficiency in type 2 diabetic patients. METHODS: A total of 179 type 2 diabetic patients were selected from among outpatients and divided into four groups according to their albumin-to-creatinine ratio: patients with normoalbuminuria (n = 86), patients with microalbuminuria (n = 44), patients with macroalbuminuria (n = 23), and patients on hemodialysis (n = 26). The serum HMW adiponectin was specifically assayed with a commercially available enzyme-linked immunosorbent assay kit. RESULTS: The HMW adiponectin levels were higher in patients on hemodialysis (17.1 +/- 8.2 microg/ml) and in those with macroalbuminuria (14.3 +/- 8.7 microg/ml) than in patients with normoalbuminuria (7.2 +/- 5.6 microg/ml) and microalbuminuria (10.8 +/- 7.0 microg/ml). Univariate linear regression analysis showed that the HMW adiponectin concentrations correlated negatively with the estimated glomerular filtration rate in patients with normoalbuminuria, microalbuminuria, and macroalbuminuria (r = -0.42, p < 0.001). Multiple stepwise regression analysis disclosed that estimated glomerular filtration rate, pioglitazone therapy, gender differences, and systolic blood pressure were independently associated with HMW adiponectin levels (r = 0.56). CONCLUSIONS: The serum HMW adiponectin concentrations are higher in type 2 diabetic patients with nephropathy, and these levels are also associated with renal insufficiency. Copyright (c) 2006 S. Karger AG, Basel.
BACKGROUND/AIM: Adiponectin, an adipocyte-derived protein, has been shown to exert antidiabetic, anti-inflammatory, and antiatherosclerotic effects. Although recent reports show an increase in the total adiponectin levels in chronic kidney diseasepatients and in patients with end-stage renal disease, the nature of biodegradation and renal involvement of adiponectin is largely unknown. We aimed at determining whether the high-molecular-weight (HMW) complex of adiponectin is associated with renal insufficiency in type 2 diabeticpatients. METHODS: A total of 179 type 2 diabeticpatients were selected from among outpatients and divided into four groups according to their albumin-to-creatinine ratio: patients with normoalbuminuria (n = 86), patients with microalbuminuria (n = 44), patients with macroalbuminuria (n = 23), and patients on hemodialysis (n = 26). The serum HMW adiponectin was specifically assayed with a commercially available enzyme-linked immunosorbent assay kit. RESULTS: The HMW adiponectin levels were higher in patients on hemodialysis (17.1 +/- 8.2 microg/ml) and in those with macroalbuminuria (14.3 +/- 8.7 microg/ml) than in patients with normoalbuminuria (7.2 +/- 5.6 microg/ml) and microalbuminuria (10.8 +/- 7.0 microg/ml). Univariate linear regression analysis showed that the HMW adiponectin concentrations correlated negatively with the estimated glomerular filtration rate in patients with normoalbuminuria, microalbuminuria, and macroalbuminuria (r = -0.42, p < 0.001). Multiple stepwise regression analysis disclosed that estimated glomerular filtration rate, pioglitazone therapy, gender differences, and systolic blood pressure were independently associated with HMW adiponectin levels (r = 0.56). CONCLUSIONS: The serum HMW adiponectin concentrations are higher in type 2 diabeticpatients with nephropathy, and these levels are also associated with renal insufficiency. Copyright (c) 2006 S. Karger AG, Basel.
Authors: C Menzaghi; S De Cosmo; M Copetti; L Salvemini; C De Bonis; D Mangiacotti; G Fini; F Pellegrini; V Trischitta Journal: Diabetologia Date: 2011-01-13 Impact factor: 10.122
Authors: I Kacso; A Lenghel; C I Bondor; D Moldovan; C Rusu; C Nita; N Hancu; M Gherman Caprioara; G Kacso Journal: Int Urol Nephrol Date: 2011-10-13 Impact factor: 2.370
Authors: S Mazaki-Tovi; R Romero; J P Kusanovic; O Erez; E Vaisbuch; F Gotsch; P Mittal; G N Than; C Nhan-Chang; T Chaiworapongsa; S Edwin; N Camacho; J K Nien; S S Hassan Journal: J Matern Fetal Neonatal Med Date: 2008-11
Authors: C K Wong; A W Y Ho; P C Y Tong; C Y Yeung; A P S Kong; S W M Lun; J C N Chan; C W K Lam Journal: Clin Exp Immunol Date: 2007-04-11 Impact factor: 4.330